Efficacy and safety of oral minocycline hydrochloride 40 mg extended-release capsules (DFD-29) versus doxycycline in rosacea: a systematic review and meta-analysis.
Laura Ghanem, Cristina Sicorschi Gutu, Daniela Lucía Mendoza-Millán et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of oral minocycline hydrochloride 40 mg extended-release capsules (DFD-29) compared to doxycycline in treating rosacea. Analyzing data from three randomized controlled trials involving 643 patients, DFD-29 significantly improved the likelihood of achieving a successful Investigator Global Assessment treatment success score (OR 2.51, P < 0.001).
Key findings
- DFD-29 significantly increased the likelihood of achieving a successful IGA-TS score compared to doxycycline (OR 2.51, P < 0.001).
- The DFD-29 40 mg group had a greater reduction in inflammatory lesion counts than the doxycycline group (mean difference -4.56, P < 0.001).
- No significant differences in treatment-emergent adverse events were observed across groups (OR 0.96, P = 0.87).
Why it matters
The findings suggest that DFD-29 at 40 mg daily may offer a more effective and well-tolerated treatment option for patients with moderate-to-severe rosacea, potentially expanding therapeutic choices in this chronic skin condition.